GlassScriptPhysician profile
Lex Philip Leonhardt
NPI 1386104024
$2,217.74
in general payments reported to CMS, 2019-2025
16 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $107 · 2023: $1,177 · 2024: $783 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,010 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.36 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $434.52 | 2023-2024 | Libtayo |
| Amgen INC. | $275.45 | 2024-2025 | Lumakras, Imdelltra (Amg757) |
| E.R. Squibb & Sons, L.L.C. | $248.98 | 2023-2024 | Opdivo, Reblozyl |
| Sobi, INC | $207.09 | 2023-2024 | |
| Pfizer INC. | $198.73 | 2024 | |
| Jazz Pharmaceuticals INC. | $124.33 | 2023 | Zepzelca |
| Glaxosmithkline, LLC. | $123.06 | 2023 | Ojjaara |
| Tempus Ai, INC | $121.27 | 2024-2025 | Xt Cdx |
| Mirati Therapeutics, INC. | $114.55 | 2023 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $107.39 | 2020 | |
| Seagen INC. | $99.99 | 2023 | |
| Gilead Sciences, INC. | $50.45 | 2023 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $38.08 | 2024 | |
| Celgene Corporation | $26.05 | 2023 | Pomalyst |
| Merck Sharp & Dohme LLC | $24.13 | 2024 | Keytruda |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $23.67 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lex Leonhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.